Spots Global Cancer Trial Database for apheresis
Every month we try and update this database with for apheresis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | NCT00006184 | Multiple Myelom... | Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | NCT00396201 | Hodgkin's Disea... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi | |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | NCT00968396 | Multiple Myelom... | Apheresis Stem Cell Trans... Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | NCT00396383 | Multiple Myelom... | plerixafor | 18 Years - 75 Years | Sanofi | |
| Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT00067639 | Multiple Myelom... | Pegfilgrastim (... Apheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | NCT00051311 | Hematologic Neo... | Stem cell trans... Fludarabine Cyclophosphamid... Etoposide Doxorubicin Vincristine Prednisone Methotrexate Cyclosporine Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma | NCT01547806 | Plasma Cell Mye... Multiple Myelom... | Filgrastim Plerixafor Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer | NCT00923741 | Non-Small Cell ... | Talactoferrin Apheresis | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT00067639 | Multiple Myelom... | Pegfilgrastim (... Apheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) | NCT02419170 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Standard of car... Apheresis Cyclophosphamid... Personalized ma... | 18 Years - | Washington University School of Medicine | |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT00984165 | Hodgkin's Lymph... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | Single fraction... Donor Lymphocyt... Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | NCT00006184 | Multiple Myelom... | Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer | NCT00001507 | Breast Neoplasm Neoplasm Metast... | Monoclonal Anti... Monoclonal Anti... Monoclonal Anti... Baxter Isolex 3... Ceprate SC | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes | NCT00048100 | Leukemia, Myelo... | Apheresis Stem Cell Trans... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia | NCT02964325 | Hematologic Mal... Hypoproliferati... | Mirasol platele... Reference plate... | - | Terumo BCTbio | |
| Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy | NCT00001440 | Breast Neoplasm Neoplasm Metast... | Autologous T ce... Interleukin-2 | - | National Institutes of Health Clinical Center (CC) | |
| The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | NCT00001432 | Chronic Myeloid... Healthy Hematologic Neo... Lymphoma | - | National Institutes of Health Clinical Center (CC) | ||
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) | NCT02419170 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Standard of car... Apheresis Cyclophosphamid... Personalized ma... | 18 Years - | Washington University School of Medicine | |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | NCT00396201 | Hodgkin's Disea... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi | |
| Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT00067639 | Multiple Myelom... | Pegfilgrastim (... Apheresis | 18 Years - | M.D. Anderson Cancer Center | |
| Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | NCT02098109 | Multiple Myelom... Lymphoma, Non-H... | XM02 Filgrastim Filgrastim Apheresis Plerixafor Stem Cell Trans... | 18 Years - | Washington University School of Medicine | |
| AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | NCT00396201 | Hodgkin's Disea... | G-CSF Plus Pler... | 18 Years - 70 Years | Sanofi | |
| TCR Alpha/Beta and CD19-deplete Haplo-HSCT | NCT05288595 | Pediatric Patie... Hematologic Mal... Other Hematolog... | CliniMACS Plus ... | 31 Days - 30 Years | University of Colorado, Denver | |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | NCT04981119 | Solid Tumor, Ad... Colorectal Canc... Non Small Cell ... Pancreatic Canc... CRC NSCLC Pancreas Cancer Mesothelioma Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Mesothelioma, M... Mesothelioma; L... Cancer | Apheresis Next Generation... Long Range NGS ... | 18 Years - | A2 Biotherapeutics Inc. | |
| Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy | NCT00001440 | Breast Neoplasm Neoplasm Metast... | Autologous T ce... Interleukin-2 | - | National Institutes of Health Clinical Center (CC) | |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma | NCT01547806 | Plasma Cell Mye... Multiple Myelom... | Filgrastim Plerixafor Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | NCT00651937 | Multiple Myelom... Primary Amyloid... | Melphalan Stem Cell Infus... Questionnaires Granulocyte-col... Apheresis | 60 Years - | M.D. Anderson Cancer Center | |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | NCT00968396 | Multiple Myelom... | Apheresis Stem Cell Trans... Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma | NCT00001832 | Melanoma Neoplasm Metast... | gp100:209-217 (... Montanide ISA-5... IL-2 MART-1:26-35(27... Abl cells Fludarabine Cyclophosphamid... GCSF (Growth co... Apheresis | 7 Years - | National Institutes of Health Clinical Center (CC) | |
| Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | NCT00733824 | Lymphoma, Non-H... Hodgkin Disease | AMD3100 G-CSF Apheresis | 18 Years - 75 Years | Washington University School of Medicine | |
| Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia | NCT02964325 | Hematologic Mal... Hypoproliferati... | Mirasol platele... Reference plate... | - | Terumo BCTbio | |
| Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas | NCT01329900 | Lymphoma | Ofatumumab Ifosfamide Etoposide Mesna G-CSF Stem Cell Colle... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| TCR Alpha/Beta and CD19-deplete Haplo-HSCT | NCT05288595 | Pediatric Patie... Hematologic Mal... Other Hematolog... | CliniMACS Plus ... | 31 Days - 30 Years | University of Colorado, Denver | |
| Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant | NCT01174082 | Myeloma | KLH Vaccine KLH-id Vaccine GM-CSF Apheresis Donor Lymphocyt... | 18 Years - 70 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
